Olanzapine
SGA • Last reviewed 2025-09-23
Brands: Zyprexa
Sources updated 2025 • 1 references
General Information
Indicated for: Schizophrenia; acute and maintenance treatment of manic/mixed episodes (bipolar I); with fluoxetine for bipolar depression. Second‑generation antipsychotic (SGA) Also available as a long‑acting injectable (see LAI section below).
Dosage & Administration
Typical dose range: 10–20 mg/day
Indications (label)
Schizophrenia; acute and maintenance treatment of manic/mixed episodes (bipolar I); with fluoxetine for bipolar depression.
View labelExact
Mechanism (brief)
Antagonist at 5-HT2A and D2; strong H1 and muscarinic activity.
Metabolism & Half‑life
- Metabolism: Hepatic (CYP1A2, minor 2D6); smoking induces clearance.
- Half‑life: ~30 h (range ~20–54 h).
Therapeutic Drug Monitoring (TDM)
Recommended: No
Long‑acting injectable (LAI)
References
- Olanzapine labelExact (2025)
- Comparative effects of 18 antipsychotics on metabolic function in schizophrenia: systematic review and network meta-analysis. — The Lancet Psychiatry (2020)
- Metabolic effects of olanzapine: systematic review — Systematic review (2019)
- Olanzapine/fluoxetine for bipolar depression: randomized trials — RCTs (2016)